Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.44 |
| ▸ | NPC1 | O15118 | 11/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492438 | 0.94 | NPC1 (0.44) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5779652 | 0.89 | NPC1 (0.49) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5779958 | 0.84 | NPC1 (0.62) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5778441 | 0.84 | RAB9A (0.54) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5783688 | 0.84 | NPC1 (0.57) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5780781 | 0.84 | RAB9A (0.46) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5778507 | 0.84 | KMT2A (0.50) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5781867 | 0.84 | RAB9A (0.61) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5495173 | 0.83 | NPC1 (0.57) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5778753 | 0.83 | FABP7 (0.49) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | claimed |
| US-6998407-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-07-01 | — | — | US | claimed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-15 | — | — | US | claimed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-6998407-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | disclosed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | CCL11, CCR1, CCR2 | RAB9A 3198/4885NPC1 332/4885KMT2A 4833/4885 |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | RAB9A 3041/4885NPC1 689/4885KMT2A 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.